Payment overview · 2025
General Payments
$2,603.53
153 reported records · 26 companies
Healthcare provider profile · identity verified
Michael Wayne Peters, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ALBERTVILLE, AL · NPI 1477501906
Verified facts
What the public records show
CMS Open Payments records show Michael Wayne Peters, M.D. received $2,603.53 in general payments during 2025 across 153 reported records.
ABBVIE INC. accounted for 17.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Otezla, Ozempic, Rybelsus, Trelegy Ellipta, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 347 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 172 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 280 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Gemtesa by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trintellix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $456.04 | 17.5% | 31 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $277.20 | 10.7% | 16 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $259.52 | 10.0% | 15 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $226.21 | 8.7% | 19 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $211.19 | 8.1% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $174.92 | 6.7% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $137.91 | 5.3% | 7 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $129.16 | 5.0% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $115.31 | 4.4% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $114.77 | 4.4% | 7 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $81.31 | 3.1% | 4 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $61.61 | 2.4% | 3 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $48.04 | 1.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.58 | 1.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.99 | 1.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.62 | 1.2% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $26.01 | 1.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.19 | 0.8% | 1 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $21.63 | 0.8% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $19.18 | 0.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $19.11 | 0.7% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.79 | 0.7% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $17.36 | 0.7% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.07 | 0.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $13.96 | 0.5% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.85 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,603.53 | 153 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $223.52 | 20 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $211.19 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $199.69 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $178.72 | 17 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $174.92 | 9 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $162.97 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $160.75 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $142.56 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $142.16 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $137.91 | 7 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $129.16 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $115.31 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $113.30 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $101.04 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $101.04 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $81.31 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $65.42 | 6 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $61.61 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $59.77 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $46.58 | 2 | 2025 |
Source payment records
|
|||||
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $32.49 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.62 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.06 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $28.03 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $26.01 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS GO v2 HOME Normalized: renasys go v2 home |
Device | Smith+Nephew, Inc. | $24.72 | 1 | 2025 |
Source payment records
|
|||||
| GRAFIX Normalized: grafix |
Biological | Smith+Nephew, Inc. | $23.32 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| 3M Cavilon Normalized: 3m cavilon |
Device | Solventum Corporation | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| KerraMax Care Normalized: kerramax care |
Device | Solventum Corporation | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| PROMOGRAN PRISMA Normalized: promogran prisma |
Device | Solventum Corporation | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $18.79 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $17.36 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $13.96 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 315 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 347 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 52 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 173 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 172 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 280 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 59 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
58 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
80 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
347 | 64 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
173 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
173 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
172 | 35 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
280 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
315 | 66 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
52 | 14 |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 967 | 158 |
| Levothyroxine Sodium | Levothyroxine Sodium | 948 | 230 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 722 | 197 |
| Atorvastatin Calcium | Atorvastatin Calcium | 714 | 215 |
| Metoprolol Succinate | Metoprolol Succinate | 691 | 189 |
| Pantoprazole Sodium | Pantoprazole Sodium | 690 | 181 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 674 | 103 |
| Omeprazole | Omeprazole | 520 | 145 |
| Losartan Potassium | Losartan Potassium | 448 | 121 |
| Tramadol Hcl | Tramadol Hcl | 447 | 93 |
| Furosemide | Furosemide | 416 | 123 |
| Amlodipine Besylate | Amlodipine Besylate | 407 | 121 |
| Lisinopril | Lisinopril | 377 | 117 |
| Hydrochlorothiazide | Hydrochlorothiazide | 359 | 104 |
| Clonazepam | Clonazepam | 356 | 52 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 349 | 105 |
| Farxiga | Dapagliflozin Propanediol | 347 | 64 |
| Tamsulosin Hcl | Tamsulosin Hcl | 339 | 87 |
| Escitalopram Oxalate | Escitalopram Oxalate | 332 | 99 |
| Metformin Hcl Er | Metformin Hcl | 330 | 93 |
| Potassium Chloride | Potassium Chloride | 326 | 75 |
| Quetiapine Fumarate | Quetiapine Fumarate | 324 | 62 |
| Duloxetine Hcl | Duloxetine Hcl | 321 | 76 |
| Eliquis | Apixaban | 315 | 66 |
| Trazodone Hcl | Trazodone Hcl | 309 | 83 |
| Zolpidem Tartrate | Zolpidem Tartrate | 301 | 44 |
| Meloxicam | Meloxicam | 294 | 91 |
| Ozempic | Semaglutide | 280 | 53 |
| Ezetimibe | Ezetimibe | 269 | 81 |
| Simvastatin | Simvastatin | 256 | 76 |
| Alprazolam | Alprazolam | 252 | 35 |
| Montelukast Sodium | Montelukast Sodium | 250 | 66 |
| Glimepiride | Glimepiride | 249 | 73 |
| Sertraline Hcl | Sertraline Hcl | 243 | 56 |
| Doxycycline Hyclate | Doxycycline Hyclate | 242 | 200 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 238 | 36 |
| Temazepam | Temazepam | 229 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 223 | 58 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 217 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 207 | 62 |
| Carvedilol | Carvedilol | 203 | 58 |
| Allopurinol | Allopurinol | 198 | 53 |
| Famotidine | Famotidine | 193 | 44 |
| Jardiance | Empagliflozin | 173 | 34 |
| Diclofenac Sodium | Diclofenac Sodium | 172 | 55 |
| Mounjaro | Tirzepatide | 172 | 35 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 160 | 46 |
| Baclofen | Baclofen | 152 | 54 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 152 | 31 |
| Pregabalin | Pregabalin | 152 | 29 |
| Dicyclomine Hcl | Dicyclomine Hcl | 145 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 44 |
| Donepezil Hcl | Donepezil Hcl | 142 | 33 |
| Celecoxib | Celecoxib | 138 | 32 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 134 | 49 |
| Fenofibrate | Fenofibrate | 129 | 38 |
| Lansoprazole | Lansoprazole | 128 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 45 |
| Ondansetron Odt | Ondansetron | 124 | 56 |
| Tresiba Flextouch U-200 | Insulin Degludec | 121 | 27 |
| Metformin Hcl | Metformin Hcl | 117 | 37 |
| Ropinirole Hcl | Ropinirole Hcl | 115 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 114 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 114 | 32 |
| Morphine Sulfate Er | Morphine Sulfate | 111 | 11 |
| Lorazepam | Lorazepam | 108 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 30 |
| Warfarin Sodium | Warfarin Sodium | 103 | 19 |
| Fluconazole | Fluconazole | 100 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 41 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 98 | 73 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 98 | 32 |
| Myrbetriq | Mirabegron | 97 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 97 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 23 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 95 | 23 |
| Prednisone | Prednisone | 94 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 88 | 22 |
| Methocarbamol | Methocarbamol | 86 | 20 |
| Telmisartan | Telmisartan | 86 | 27 |
| Januvia | Sitagliptin Phosphate | 84 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 81 | 14 |
| Lovastatin | Lovastatin | 80 | 17 |
| Synthroid | Levothyroxine Sodium | 80 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 78 | 28 |
| Etodolac Er | Etodolac | 77 | 23 |
| Xarelto | Rivaroxaban | 76 | 14 |
| Nystatin | Nystatin | 75 | 36 |
| Buspirone Hcl | Buspirone Hcl | 74 | 19 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 74 | 14 |
| Mirtazapine | Mirtazapine | 73 | 13 |
| Estradiol | Estradiol | 71 | 18 |
| Meclizine Hcl | Meclizine Hcl | 71 | 30 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 17 |
| Solifenacin Succinate | Solifenacin Succinate | 64 | 20 |
| Atenolol | Atenolol | 62 | 17 |
| Memantine Hcl | Memantine Hcl | 62 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | suppressed |
| Modafinil | Modafinil | 60 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 13 |
| Rybelsus | Semaglutide | 59 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 58 | 12 |
| Linzess | Linaclotide | 58 | 20 |
| Betamethasone Valerate | Betamethasone Valerate | 57 | 41 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 56 | suppressed |
| Eszopiclone | Eszopiclone | 56 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 55 | 15 |
| Spironolactone | Spironolactone | 55 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 38 |
| Colchicine | Colchicine | 53 | 18 |
| Gemtesa | Vibegron | 52 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 52 | 12 |
| Valsartan | Valsartan | 52 | 11 |
| Bupropion Xl | Bupropion Hcl | 50 | 14 |
| Tradjenta | Linagliptin | 49 | suppressed |
| Finasteride | Finasteride | 48 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 48 | suppressed |
| Aripiprazole | Aripiprazole | 46 | suppressed |
| Levofloxacin | Levofloxacin | 45 | 35 |
| Pitavastatin Calcium | Pitavastatin Calcium | 45 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 30 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | suppressed |
| Vraylar | Cariprazine Hcl | 43 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Entresto | Sacubitril/Valsartan | 41 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 16 |
| Naproxen | Naproxen | 37 | suppressed |
| Diazepam | Diazepam | 36 | suppressed |
| Metronidazole | Metronidazole | 36 | 31 |
| Terbinafine Hcl | Terbinafine Hcl | 36 | 22 |
| Zaleplon | Zaleplon | 36 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Topiramate | Topiramate | 35 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 32 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 32 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 32 | suppressed |
| Buprenorphine | Buprenorphine | 31 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | 11 |
| Lidocaine | Lidocaine | 30 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 12 |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Oxazepam | Oxazepam | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 25 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 25 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Fluorouracil | Fluorouracil | 24 | 20 |
| Metolazone | Metolazone | 24 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 22 |
| Colesevelam Hcl | Colesevelam Hcl | 23 | 11 |
| Lagevrio (Eua) | Molnupiravir | 23 | 23 |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Fluocinonide | Fluocinonide | 21 | 11 |
| Imipramine Hcl | Imipramine Hcl | 21 | suppressed |
| Nystop | Nystatin | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 20 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 20 | suppressed |
| Otezla | Apremilast | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Niacin Er | Niacin | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 14 |
| Daptomycin | Daptomycin | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 13 | suppressed |
| Alprazolam Xr | Alprazolam | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Glipizide | Glipizide | 13 | suppressed |
| Larin Fe | Norethindrone-E.Estradiol-Iron | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | 11 |
| Ramelteon | Ramelteon | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Zypitamag | Pitavastatin Magnesium | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Etodolac | Etodolac | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,603.53 · 153 records | ABBVIE INC. | 3M Cavilon, ABRYSVO, AIRSUPRA, Ambulatory Monitoring & Diagnostics Undivided, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, DALVANCE, Dexcom G6 Transmitter, ELIQUIS, EVENITY, FARXIGA, Fluad, GEMTESA, GRAFIX, JARDIANCE, Kerendia, KerraMax Care, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROMOGRAN PRISMA, QULIPTA, RENASYS GO v2 HOME, REPATHA, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, XYOSTED, ZAVZPRET, ZTLido | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error